Core Points - The company will hold a Q3 2025 earnings presentation on December 4, 2025, from 16:00 to 17:00 [2][4] - The presentation will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3] - Investors can submit questions from November 27, 2025, to December 3, 2025, before 16:00 [2][5] Meeting Details - The meeting will feature key personnel including the Chairman, President, CFO, Board Secretary, and Independent Director [4] - Investors can participate online via the Shanghai Stock Exchange Roadshow Center [4][5] - The company will address commonly asked questions during the presentation [3][5]

Investment Rating - The investment rating for the company is "Buy" [1][7] Core Insights - The company has achieved significant results from its marketing model transformation, optimizing operational efficiency. The sales expense ratio for the first three quarters of 2025 was 47.19%, a decrease of 2.69 percentage points year-on-year, indicating improved operational efficiency [7] - The innovative drug pipeline has established a matrix layout, with the company's independent innovation capabilities being validated. Key drugs are in various stages of clinical trials, including KC1036 in Phase III and KC1086 completing Phase I [7] - Revenue forecasts for 2025 to 2027 are projected at 9.11 billion yuan, 10.63 billion yuan, and 12.14 billion yuan, with year-on-year growth rates of 10.4%, 16.7%, and 14.2% respectively. Net profit attributable to shareholders is expected to be 1.69 billion yuan, 2.03 billion yuan, and 2.42 billion yuan, with growth rates of 299.8%, 20.2%, and 19.2% respectively [7] Financial Summary - The latest closing price of the company's stock is 44.40 yuan, with a market capitalization of 70.75 billion yuan and a total share capital of 1.59 billion shares [1] - The company's current price-to-earnings (PE) ratio is 123.87, and the price-to-book (PB) ratio is 2.21 [1] - The revenue for 2024 is projected at 8.25 billion yuan, with a revenue growth rate of -10.3%. The net profit for the same year is expected to be 0.43 billion yuan, reflecting a significant decline of 71.9% [4][8]

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-074 北京康辰药业股份有限公司 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 27 日（星期四）至 12 月 03 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@konruns.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 北京康辰药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 04 日（星期 四）下午 16:00-17:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题 进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允 许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 12 月 04 ...

Market Overview - The biopharmaceutical sector increased by 0.83% on November 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Biopharmaceutical Sector - Jinke (688670) closed at 25.75, up 19.99% with a trading volume of 92,200 shares [1] - Hualan Biological (301207) closed at 23.33, up 11.25% with a trading volume of 250,500 shares [1] - Saiseng Pharmaceutical (300485) closed at 11.95, up 5.19% with a trading volume of 168,000 shares [1] - Other notable gainers include Bohui Innovation (300318) at 6.84 (+3.32%) and Dongbao Biological (300239) at 5.72 (+3.25%) [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 40.88 million yuan from institutional investors, while retail investors experienced a net outflow of 147 million yuan [2] - The sector's overall capital flow indicates a strong interest from institutional investors despite retail selling pressure [2] Individual Stock Capital Flow - Jinke (688670) had a net inflow of 39.66 million yuan from institutional investors, while retail investors showed a net outflow of 13.72 million yuan [3] - Other stocks like Watson Bio (300142) and Hualan Bio (002007) also experienced significant net inflows from institutional investors, indicating positive sentiment [3] - Conversely, stocks like Dongbao Biological (300239) and Bohui Innovation (300318) faced net outflows from retail investors, suggesting mixed investor sentiment [3]

Market Overview - The biopharmaceutical sector experienced a decline of 1.94% on November 17, with Kexing Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Bohui Innovation: Closed at 8.00, up 2.56% with a trading volume of 824,300 shares [1] - ST Weiming: Closed at 8.31, up 2.21% with a trading volume of 60,800 shares [1] - Major decliners included: - Kexing Pharmaceutical: Closed at 34.59, down 7.88% with a trading volume of 53,300 shares [2] - Jinwei: Closed at 26.05, down 7.06% with a trading volume of 123,100 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 1.211 billion yuan from institutional investors, while retail investors contributed a net inflow of 893 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Wanzhe Co.: Net outflow of 37.20 million yuan from institutional investors [3] - Olin Bio: Net inflow of 13.81 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different companies within the sector [3]

Investment Rating - The investment rating for the company is "Buy" and is maintained [5]. Core Insights - The company reported a total revenue of 692 million yuan for the first three quarters of 2025, representing a year-on-year increase of 7.10%. The net profit attributable to shareholders was 128 million yuan, up 13.19% year-on-year, while the net profit after deducting non-recurring items reached 133 million yuan, reflecting a significant increase of 25.90% year-on-year. The financial performance is stable, with positive progress in research and development and effective marketing transformation [3][9]. Summary by Sections Financial Performance - For the first three quarters of 2025, total revenue was 692 million yuan (up 7.10% year-on-year), net profit attributable to shareholders was 128 million yuan (up 13.19% year-on-year), and net profit after deducting non-recurring items was 133 million yuan (up 25.90% year-on-year). In the third quarter alone, total revenue was 231 million yuan (down 4.12% year-on-year), with net profit of 37 million yuan (up 9.06% year-on-year) and net profit after deducting non-recurring items also at 37 million yuan (up 17.98% year-on-year) [3][9]. Research and Development - The company has made significant progress in its R&D pipeline, with KC1086 completing the first subject enrollment in Phase I clinical trials. KC1036 is progressing normally in Phase III clinical trials, and ZY5301 is in active communication with the National Medical Products Administration regarding its market registration application. The company is also advancing preclinical projects KC1101 and KC5827, aiming to enter clinical research soon. There are over 10 projects in the pre-research screening stage, covering various fields such as hemostasis, bone metabolism, and oncology, with 2-3 projects expected to be initiated each year [9]. Marketing Transformation - The company has successfully transitioned from a single alliance model to a dual-driven strategy that emphasizes self-operated models while maintaining collaborative development. This transformation has led to significant improvements in professional promotion, brand building, market access, and customer coverage. The core product "Su Ling" has seen substantial operational benefits, and the overseas business of "Mi Ge Xi" has also achieved continuous growth [9]. Profit Forecast - The company forecasts net profits attributable to shareholders of 160 million yuan, 185 million yuan, and 215 million yuan for 2025, 2026, and 2027, respectively. Corresponding earnings per share (EPS) are projected to be 1.00 yuan, 1.16 yuan, and 1.35 yuan [9].

Core Viewpoint - Kangchen Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 105.40%, despite recent fluctuations in the short term [2]. Financial Performance - For the period from January to September 2025, Kangchen Pharmaceutical achieved a revenue of 6.92 billion yuan, representing a year-on-year growth of 7.10%. The net profit attributable to the parent company was 1.28 billion yuan, reflecting a year-on-year increase of 13.19% [2]. - The company has distributed a total of 4.37 billion yuan in dividends since its A-share listing, with 1.75 billion yuan distributed over the past three years [3]. Stock Market Activity - As of November 13, Kangchen Pharmaceutical's stock price was 47.08 yuan per share, with a market capitalization of 75.03 billion yuan. The stock experienced a 2.06% increase during the trading session [1]. - The stock has been active on the龙虎榜 (top trading list) four times this year, with the most recent appearance on September 1 [2]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 10,700, up by 7.18% from the previous period. The average number of circulating shares per shareholder decreased by 6.12% to 14,806 shares [2]. - New institutional shareholders include several funds, such as Qianhai Kaiyuan and Huatai-PineBridge, which have recently entered the top ten circulating shareholders list [3].

Group 1 - The company has approved a share repurchase plan using its own or raised funds, with a total repurchase amount between RMB 50 million and RMB 100 million, and a maximum repurchase price of RMB 82 per share, within a 12-month period [1] Group 2 - As of October 31, 2025, the company has repurchased a total of 397,400 shares, representing 0.25% of the total share capital, with a total expenditure of RMB 20,161,793, at a maximum price of RMB 51.40 per share and a minimum price of RMB 49.69 per share [2] Group 3 - The company will adhere to relevant regulations and make repurchase decisions based on market conditions, ensuring timely information disclosure regarding the progress of the share repurchase [3]

Core Viewpoint - Kangchen Pharmaceutical announced a share repurchase plan, having repurchased a total of 397,400 shares, which represents 0.25% of the company's total share capital [2] Summary by Category - **Company Actions** - The company has completed a share repurchase of 397,400 shares as of October 31, 2025 [2] - This repurchase accounts for 0.25% of the total share capital of the company [2]

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-073 北京康辰药业股份有限公司 关于股份回购进展公告 三、其他事项 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/10/16，由董事会提议 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 2025 10 | 10 | 月 | 15 | 日~2026 | 年 | 月 | 14 | 日 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | | | | 累计已回购股数 | 397,400股 | | | | | | | | | | 累计已回购股数占 ...